Ocrelizumab – Primary Progressive Multiple Sclerosis

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

ocrelizumab

Ocrelizumab is a humanized monoclonal antibody currently under clinical investigation and development by the Swiss pharmaceutical company Roche. The therapy is targeted against mature B-lymphocytes with CD20 markers on their surface, giving the drug an immunosuppressive function that might be useful in normalizing the rates of immune attacks made by the host’s immune system against its own myelinated neurons, which form the main pathogenesis of multiple sclerosis (MS).

Read more: http://bit.ly/1JUBLqj

The Multiple Sclerosis Podcast



Video